A Realworld Study of Acute Respiratory Distress Syndrome in China
CHARDSnet
1 other identifier
observational
400
1 country
1
Brief Summary
ARDS is a critical respiratory disease caused by endogenous and exogenous factors. The mortality of ARDS varies from 30 to 70%. In 2012, a new international diagnostic criterion has been put forward. Yet, its feasibility, reliability and validity need to be tested. Meanwhile, the correlation of different severity and prognosis remains unclear. As so far, the epidemiological information about ARDS in China is lacking. Investigators plan to conduct a multi-center observational study（real-life study） to investigate the risk factors, morbidity, management and prognosis of ARDS in China, in order to facilitate standardization of diagnosis and management of ARDS and provide basic data and idea for further clinical intervention studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 5, 2016
CompletedFirst Posted
Study publicly available on registry
November 29, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2019
CompletedNovember 29, 2016
November 1, 2016
2.5 years
April 5, 2016
November 23, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
the 28days mortality after the diagnosis of ARDS
28days
Secondary Outcomes (11)
Length of ICU stay
90 days
Ventilation free days
28 days
Incidence of ARDS
2 years
Severity of patients
2 years
Adverse events related to treatment
90 days
- +6 more secondary outcomes
Eligibility Criteria
This research plans to enroll 400 hospitalized patients (≥ 18 years old with main diagnosis as ARDS). Sample size estimation is based on estimated mortality of ARDS hospitalized patients (\~5%). Study patients will be recruited from 20 hospitals across China,each hospital will recruit 20 patients. Hospital selection follows a multi-stage sampling strategy.
You may qualify if:
- ≥18 years of age; hospitalized patients with main diagnosis as ARDS.
You may not qualify if:
- \<18 years of age
- Patients or their families refused to participate in the study
- Patients diagnosed as COPD, pulmonary fibrosis or bronchiectasis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- China-Japan Friendship Hospitallead
- PLA General Hospitalcollaborator
- Second Xiangya Hospital of Central South Universitycollaborator
- Xiangya No.1 Hospital of Central South Universitycollaborator
- The Second Affiliated Hospital of Chongqing Medical Universitycollaborator
- Beijing Chao Yang Hospitalcollaborator
- First Affiliated Hospital of Xinjiang Medical Universitycollaborator
- First Hospital Affiliated to China Medical Universitycollaborator
- Nanjing General Hospitalcollaborator
- Peking University First Hospitalcollaborator
- Third Hospital Affiliated to Neimenggu Medical Universitycollaborator
- Second Hospital Affiliated to Hebei Medical Universitycollaborator
- Qilu Hospital of Shandong Universitycollaborator
- First Hospital Affiliated to Anhui Medical Universitycollaborator
- Ruijin Hospitalcollaborator
- Beijing Hospitalcollaborator
- Peking Union Medical College Hospitalcollaborator
- No.3 Hospital of Peking Universitycollaborator
- Fuxing Hospitalcollaborator
- Fujian Provincial Hospitalcollaborator
Study Sites (1)
China - Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Related Publications (2)
Yang H, Xia J, Huang X, Bai Y, Jin D, Nouraie SM, McVerry BJ, Morris A, Kitsios GD, Wang C, Zhan Q. Generalisability of ARDS biological subphenotype models in Asians: an international, multicentre, prospective biomarker study. Thorax. 2025 Oct 29:thorax-2025-223421. doi: 10.1136/thorax-2025-223421. Online ahead of print.
PMID: 41167619DERIVEDHuang X, Zhang R, Fan G, Wu D, Lu H, Wang D, Deng W, Sun T, Xing L, Liu S, Wang S, Cai Y, Tian Y, Zhang Y, Xia J, Zhan Q; CHARDSnet group. Incidence and outcomes of acute respiratory distress syndrome in intensive care units of mainland China: a multicentre prospective longitudinal study. Crit Care. 2020 Aug 20;24(1):515. doi: 10.1186/s13054-020-03112-0.
PMID: 32819400DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
April 5, 2016
First Posted
November 29, 2016
Study Start
August 1, 2015
Primary Completion
February 1, 2018
Study Completion
February 1, 2019
Last Updated
November 29, 2016
Record last verified: 2016-11